The Baker & McKenzie group will be at Bio2009 and we will be presenting with representatives from Pfizer, Abbott and MorphoSys ( German Biotech ) at the panel below. 

Track:                 Business Development
Session ID:         2617
Session Title:      Global Intellectual Property Due Diligence
Date/Time:          Wednesday, May 20, 2009 - 10:00 AM to 11:30 AM
Location:            B313, Georgia World Congress Center (Building B) - http://www.gwcc.com/  

Global Intellectual Property Due Diligence

M&A activity reached historic levels in 2007, and while activity is expected to dip in 2009, M&A will continue as companies are expected to continue to make acquisitions at fire-sale prices in an attempt to fill sluggish pipelines. All of this means that intellectual property due diligence – the process of investigating and confirming the status of IP assets – is becoming increasingly important. The panel discusses why intellectual property due diligence (IPDD) is important and how to do cost effective diligence in the global life science context. 

• Learn to prioritize assets, decide which sources to use, perform basic IPDD, and determine when deep review is needed

• Prepare an IP portfolio in advance for a smooth, hassle-free exit v.using IP issues to negotiate a lower price

• Become sensitized to differing IP rules and cultural norms in different jurisdictions